Treace Medical Concepts (TMCI)
NASDAQ:TMCI
Want to see TMCI full AI Analyst Report?
TMCI Stock Chart & Stats
$1.94
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.94
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.17 - $7.78
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$271.82M
Enterprise Value$264.15M
Total Cash (Recent Filing)$51.85M
Total Debt (Recent Filing)$13.55M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Aug 11, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding64,872,980
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit1.60
Enterprise Value/Ebitda-5.70
Forecast
1Y Price Target
$4.50Price Target Upside131.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$206.33M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~80% gross margins represent durable product-level economics and pricing power for implants and disposables. Even with current losses, these margins create a realistic path to profitability as revenue scales, enabling operating leverage and attractive incremental contribution on each procedure.
Product Portfolio Expansion And TAM GrowthAdding complementary systems and planned commercial rollouts materially broadens addressable market and reduces single-product dependency. Expanding TAM by ~$300M and new SKUs supports long-term revenue runway, cross-sell opportunities, and deeper customer relationships as surgeons adopt broader procedural solutions.
Surgeon Adoption & Procedure MomentumGrowing active surgeon base and increasing adoption indicate durable pull-through for implants and consumables, which drives recurring per-case revenue. A sizable installed user network and rising procedure counts lower customer acquisition costs over time and support sustainable utilization growth across the portfolio.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow forces reliance on external financing or drawdown of liquidity, constraining reinvestment and strategic optionality. Even with reduced burn, ongoing cash deficits limit runway and raise execution risk if commercialization or revenue recovery is slower than planned.
Ongoing Operating And Net LossesContinued GAAP losses erode equity and indicate the company has not yet converted high product margins into sustained profitability. Persisting operating deficits reduce financial resilience, pressure returns on invested capital, and extend the timeline to durable positive earnings absent faster revenue recovery or sharper expense cuts.
Revenue Decline & ASP/mix HeadwindsDeclining revenue and adverse ASP/mix shifts signal a structural near-term headwind: lower-priced product adoption can reduce revenue even as unit penetration rises. This mix pressure can delay margin expansion at the operating level and lengthen the time needed to reach breakeven despite high gross margins.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.17 and its highest was $7.78 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $271.82M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is Aug 11, 2026 which is in 52 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.028.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.3.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,872,980 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went up 4.687%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (131.96% Upside)
$4.50 (131.96% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-69.50%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Treace Medical Concepts
Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts, Inc. is an orthopedic medical device enterprise that specializes in the development, manufacturing, and commercialization of surgical tools for foot and ankle specialists throughout the United States. A cornerstone of its product line is the Lapiplasty procedure, which enables surgeons to comprehensively correct bunions in all three dimensions, thereby offering patients significant cosmetic and medical benefits. The firm also provides the Lapiplasty Mini-Incision precision system. Furthermore, its portfolio includes instruments designed to facilitate various ancillary surgical procedures, such as akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, autograft bone harvesting, and MTP fusion. Treace Medical Concepts, Inc. was established in 2013.
TMCI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: commercial execution and product momentum are clear positives (rapid adoption of new systems, expanding TAM, high gross margins, improved cash balance and reduced cash burn expectations), but near-term financials remain challenged (Q1 revenue down 10%, larger net and EBITDA losses, and ASP/mix headwinds). Management is taking a conservative posture—reaffirming guidance while highlighting the path to lapping mix headwinds in the back half of 2026 and expecting revenue growth to return in Q4. Overall, operational improvements and promising adoption trends offset but do not yet fully overcome the near-term revenue and profitability headwinds, leaving the situation balanced between encouraging commercial traction and ongoing financial pressure.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$4.50
▲(131.96% Upside)
Technical Analysis
Ownership Overview
28.33% Insiders
8.21% Mutual Funds
20.48% Other Institutional Investors
36.13% Public Companies and
Individual Investors